[{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Defender Pharmaceuticals Reports Positive Results from Pivotal Phase III Clinical Trial of Intranasal Scopolamine for the Prevention of Nausea and Vomiting Induced by Motion","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender P.."},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Defender Pharmaceuticals Announces Submission of New Drug Application to FDA with Intranasal Scopolamine for Prevention of Nausea and Vomiting Induced by Motion in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender P.."},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Accepts Defender Pharmaceuticals\u2122 New Drug Application for Intranasal Scopolamine Gel","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2023","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender P.."},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"National Aeronautics and Space Administration","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Defender Pharmaceuticals Announces Collaboration with NASA on Two Phase 2 Clinical Trials Investigating DPI-386\u2122s Ability to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ National Aeronautics and Space Administration","highestDevelopmentStatusID":"10","companyTruncated":"Defender P.."},{"orgOrder":0,"company":"Defender Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Defender Pharmaceuticals Receives Complete Response Letter from the U.S. Food and Drug Administration for its Intranasal Scopolamine (DPI-386) New Drug Application for the Prevention of Nausea and Vomiting Induced by Motion in Adults","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"January 2024","year":"2024","type":"Not Applicable","leadProduct":"Scopolamine Hydrobromide","moa":"","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III","graph3":"Defender Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Neurology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","productSubType":"","amount2New":0,"dosageForm":"Gel","sponsorNew":"Defender Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Defender P.."}]

Find Clinical Drug Pipeline Developments & Deals for (-)-Scopolamine hydrobromide

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

(-)-Scopolamine hydrobromide

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

13 API Suppliers, 6 USDMF, 3 CEP/COS, 2 JDMF, 4 EU WC, 4 NDC API, 7 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

FINISHED DOSAGE FORMULATIONS

6 FDF Dossiers, 2 Europe, 2 Canada, 2 South Africa

RELATED EXCIPIENT COMPANIES

2 Rochem International Inc, 6 SPI Pharma, 4 DKSH, 11 Gangwal Healthcare, 2 Nanjing Well Pharmaceutical, 1 Pfanstiehl, 4 Actylis, 4 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 3 BASF, 3 Corel Pharma Chem, 5 DFE Pharma, 6 Gangwal Chemicals, 1 Ideal Cures Pvt Ltd, 2 Ingredion Pharma Solutions, 26 Kerry, 14 Microlex e.U, 1 Pharmatrans-Sanaq, 4 Pluviaendo, 2 Prachin Chemical, 24 Roquette, 1 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 9 Sigachi Industries, 3 Vasa Pharmachem, 1 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

62 Fillers, Diluents & Binders, 28 Direct Compression, 18 Lubricants & Glidants, 16 Coating Systems & Additives, 15 Thickeners and Stabilizers, 15 Co-Processed Excipients, 13 Taste Masking, 12 Film Formers & Plasticizers, 11 Granulation, 9 Disintegrants & Superdisintegrants, 7 Parenteral, 7 Controlled & Modified Release, 7 Chewable & Orodispersible Aids, 3 Emulsifying Agents, 2 Topical, 2 Coloring Agents, 1 API Stability Enhancers, 1 Soft Gelatin, 1 Rheology Modifiers

DIGITAL CONTENT

2 NEWS #PharmaBuzz

2 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

2 Finished Drug Prices

2 Finished Drug Prices

MARKET PLACE

5 APIs

5 APIs

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP, 11 JP, 2 Others

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Defender Pharmaceuticals

U.S.A

Formnext Forum

Not Confirmed

02

Defender Pharmaceuticals

U.S.A

Formnext Forum

Not Confirmed

03

Defender Pharmaceuticals

U.S.A

Formnext Forum

Not Confirmed

04

Defender Pharmaceuticals

U.S.A

Formnext Forum

Not Confirmed

05

Defender Pharmaceuticals

U.S.A

Formnext Forum

Not Confirmed